文献速递核素与放射性配体治疗肿瘤 PET/CT

神经内分泌肿瘤腹膜病变与[177Lu]DOTATATE肽受体放射性核素治疗:潜在临床并发症的治疗挑战

Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-04

该研究通过序贯[68Ga]DOTATOC PET/CT评估[177Lu]DOTATATE肽受体放射性核素治疗(PRRT)对小肠神经内分泌肿瘤(SiNETs)腹膜癌病/肠系膜纤维化(PC/MF)的疗效与安全性,并与肝转移灶对比。结果显示PC/MF功能体积治疗后不变、SUVmax仅轻度下降,肝转移灶功能体积明显缩小且SUVmax下降更大;PC/MF功能客观缓解率(fORR)呈低于肝转移灶趋势(18.7% vs 38.4%),15%患者在PRRT后三个月内发生肠梗阻。

要点

  • PC/MF对[177Lu]DOTATATE PRRT的应答低于肝转移灶,功能体积治疗后不变。
  • PC/MF与肝转移灶fORR呈18.7% vs 38.4%的较低趋势。
  • 15%患者在PRRT后三个月内发生肠梗阻,广泛腹膜病变者风险值得关注。

核心结论

  • 与肝转移灶相比,PC/MF对[177Lu]DOTATATE PRRT表现出更强的抵抗,且PRRT后三个月内发生肠梗阻的风险不可忽视,尤其在广泛腹膜病变患者中。

研究设计与样本

  • 20例小肠神经内分泌肿瘤患者接受[177Lu]DOTATATE PRRT,在治疗前、两个周期后及治疗结束时行[68Ga]DOTATOC PET/CT,测量靶病灶SUVmax与功能体积,记录消化道并发症并评估功能客观缓解率(fORR)。

主要发现

  • 17例患者为PC,1例同时有MF和PC,2例仅有MF。
  • 8例被归为高风险,12例被归为肠梗阻风险。
  • PC/MF功能体积治疗后保持不变,SUVmax仅轻度下降;肝病灶功能体积明显缩小且SUVmax下降更大。
  • 上述差异在最初两个周期后即显现,提示PC/MF应答有限;仅分析18例PC患者时获得类似显著结果。
  • PC/MF的fORR呈低于肝病灶的趋势(18.7% vs 38.4%),15%患者在PRRT后三个月内发生梗阻。

关键数值与推荐

  • PC/MF与肝病灶的fORR分别为18.7%与38.4%,原文描述为呈较低趋势。
  • 15%患者在PRRT后三个月内发生梗阻。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To address the efficacy and safety of [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) for peritoneal carcinomatosis/mesenteric fibrosis (PC/MF) with reference to liver metastases through sequential [68Ga]DOTATOC PET/CT in patients with small-intestine neuroendocrine tumors (SiNETs). METHODS: Twenty patients underwent [68Ga]DOTATOC PET/CT before PRRT (PETbefore), after two cycles (PETinterim), and at the end of treatment (PETend). SUVmax and functional volumes were measured in target lesions. Digestive complications were recorded, and functional Objective Response Rate (fORR) assessed. RESULTS: Seventeen patients presented with PC, one with both MF and PC, and two with MF only. Eight patients were classified as high-risk, and 12 as risk for intestinal obstruction. PC/MF functional volumes remained unchanged after treatment, with modest SUVmax decrease, while liver lesions showed marked functional volume reduction and greater SUVmax decrease. This divergence was evident after the first two cycles, indicating limited PC/MF response. Similar significant results were obtained considering only the 18 patients with PC. PC/MF showed a trend toward a lower fORR than liver lesions (18.7% vs. 38.4%), with 15% of patients experiencing obstruction within three months post-PRRT. CONCLUSION: PC/MF exhibit increased resistance to [177Lu]DOTATATE PRRT compared to liver metastases, with non-negligible risk of obstruction occurring within three months after PRRT, particularly in patients with extensive peritoneal disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Poterszman N, Baltzinger P, Mamulashvili Bessac D, et al. Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications. Eur J Nucl Med Mol Imaging. 2025. PMID: 40183957. doi:10.1007/s00259-025-07212-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。